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A rapid, site-selective and eﬃcient route to the
dual modification of DARPins†
Paul Moody,ab Vijay Chudasama,a Ramiz I. Nathani,a Antoine Maruani,a
Stephen Martin,b Mark E. B. Smitha and Stephen Caddick*a
Designed ankyrin repeat proteins (DARPins) are valuable tools in both
biochemistry andmedicine. Herein we describe a rapid, simple method
for the dual modification of DARPins by introduction of cysteine
mutations at specific positions that results in a vast diﬀerence in their
thiol nucleophilicity, allowing for clean sequential modification.
A leading alternative to antibody proteins for binding to mole-
cular targets are designed ankyrin repeat proteins (DARPins),1
which are small (B15 kDa), thermally stable,2 and routinely
expressed in E. coli in high yields. The ease with which DARPins
can be genetically manipulated, expressed and purified has
made them attractive tools for development in both academia
and industry.3 DARPins are small, single-domain proteins,
which consist of repeated structural units.4,5 DARPins contain
at least 1 internal repeat, flanked by N- and C-terminal capping
helices to prevent aggregation.4,5 These repeats form two anti-
parallel a-helices, and a b-hairpin. The long axes of the helices
and the b-hairpin are perpendicular, which forms a pocket that
is used as a binding site. In DARPins that have been selected to
bind to a designated target, the residues that do not form the
binding site are conserved, whereas the residues that form
the binding site are derived from randomised sequences.3
Over the years, a plethora of diﬀerent reagents for increasing
the functionality of proteins have become available. These include:
reagents for PEGylation for increased in vivo half-life,6 drugs7 or
photosensitive reagents for targeted therapy,8 fluorophores for
in-cell and in vivo imaging,9 MRI contrast agents,10 radiolabels,11
electrophiles for covalent attachment to protein targets,12 and
mimics of post-translational modification.13 Despite the sub-
stantial toolbox of reagents that could be applied to function-
alise proteins, site-selective addition of multiple reagents onto
the same protein remains a significant challenge.14
A common strategy for the controlled, selective addition of
multiple functional groups is to diﬀerentially label protein
termini using inteins,15 sortase16 or native chemical ligation17
labelling strategies. These strategies, however, are commonly
limited to the labelling of the termini, involve multiple reaction
and purification steps, and may result in loss of the attached
functional group by proteolysis.18 Another common strategy for
selective addition of multiple functional groups is to introduce
reactive unnatural amino acids into the protein sequence,19–21
which can be selectively modified in the presence of other
reactive groups and this approach has been successfully applied
to DARPins.21 However, unnatural amino acid strategies require
expensive unnatural amino acids and more complex expression
protocols.
In 2002, Ratner et al.22 proposed that if a protein contains
two free cysteines that have a suﬃcient diﬀerence in reactivity,
then the most reactive cysteine can first be selectively reacted to
completion by addition of a weakly thiol reactive reagent and
the remaining, less reactive cysteine, subsequently modified
with a highly thiol reactive reagent to generate a dual modified
protein. Although this is a powerful and useful concept, it has
brought limited success to date due to the diﬃculty in identifying
cysteines with suitable diﬀerences in reactivity – leading to
heterogeneous products and the requirement of intermediate
purification steps. Herein, for the first time, we deliver a realisa-
tion of the strategy with complete selectivity, without the need for
intermediate purification, on a protein of huge significance and
relevance. Through identification of cysteine environments with
significant differences in nucleophilicity, simple, rapid and site-
selective dual modification of DARPins has been enabled.
The model DAPRin protein that we selected for analysis is a
HER2-binding DARPin (‘‘HER2DARPin’’, PDBID: 2JAB),23,24
which contains two internal repeats. HER2 is a validated target
for the treatment of breast cancer, as demonstrated by the success
of the monoclonal antibody trastuzumab,25 and the chemically
functionalised variant trastuzumab-emtansine.26 We believe that
if DARPins could be selectively functionalised in a facile manner,
a number of useful applications would ensue, e.g. a novel route to
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the linking of DARPins with diﬀerent binding domains to
construct bi-, tri- or multi-specific constructs, or functionalisation
with a PEG chain and a cytotoxic drug to construct a targeted
therapeutic.27,28 In this study, we were interested in providing a
proof of concept for the site-selective dualmodification of DARPins.
We sought to identify two residues for mutation to cysteine that
gave vastly diﬀerent cysteine reactivity. From the first internal repeat,
all residues with a solvent-accessible surface area greater than 20 Å2
(calculated using DSSP)29 and distal to the binding site were selected
for mutation to cysteine (see Table 1). Due to DARPins comprising
conserved repeat units, it was assumed that analogous mutations
on adjacent repeats would yield similar results, thus mutations
on adjacent repeats were not initially tested. By reaction with
N-methylmaleimide, each mutant was confirmed to have a
single free cysteine (see ESI,† Fig. S13–S39).
In order to test the reactivity of the single-cysteine DARPin
mutants, reduced mutants were reacted with a weakly thiol-
reactive reagent under mild conditions, namely 1 mM 2-bromo-
N-(2-methoxyethyl)acetamide (BrAcEGMe, 5 eq.) in PBS pH 7.4
for 1 h at 4 1C. After this, the progress of the reaction was
evaluated by mass spectrometry (Table 1).
Although we observed a wide range of reactivity across the series
ofmutants evaluated, weweremost pleased to observe amutant that
reacted completely, D72C, and one that gave no reaction (within
experimental error), N69C, as this paved the way to appraise the site-
selective dual modification strategy discussed. We next sought to
determine whether equivalent mutations on adjacent repeats would
display similar reactivity (see Fig. 1). We thus generated mutations
equivalent to D72C (i.e. D39C and D105C). To our delight, these
mutants were also found to be highly reactive towards BrAcEGMe
(see ESI,† Fig S10–S12 and S43–S45). Mutations that were
equivalent to N69C (i.e. N36C and H102C) were next generated.
Gratifyingly, these mutants were found to be highly unreactive
(see ESI,† Fig. S4–S6 and S40–S42). The L135Cmutation, whichmay
have been predicted to be unreactive, showed ca. 25% reactivity
towards BrAcEGMe (see ESI,† Fig. S46–S48). This is not surprising,
however, as the L135C position is the penultimate residue on the
protein and is therefore likely to experience a different micro-
environment to N69C, N36C and H102C, due to increased flexibility
at the C-terminus.30 Recently, improved sequences for the
N-terminal31 and C-terminal30 capping helices have been described.
We found that the poor reactivity of the N36C mutation was
retained when combined with the improved N-terminal sequence
(ESI,† Fig. S7–S9). Gratifyingly, the increased stability conferred by
the improved C-terminal mutations significantly lowered the reac-
tivity of the L135C mutant (ESI,† Fig. S49–S51).
We next sought to generate DARPin dual cysteine mutants in
which the cysteines could be reacted sequentially. Using the same
HER2DARPin, we generated an N69C, D72C dual mutant in which
the cysteine residues are proximal, and anN36C, D105C dualmutant
in which the cysteine residues are distal. In order to show the
generality of our technique, we also generated an N69C, D72C
mutant of the small DARPin protein mut4,32 which has a single
internal repeat (11 kDa). In each case, we successfully demonstrated
selective addition of BrAcEGMe to one of the two cysteine residues
(see ESI,† Fig. S52–S60). In order to demonstrate that a second
functional reagent could be added to the protein in a controlled
manner, we took the HER2DARPin(N36C, D105CAcEGMe) that was
functionalised with ethylene glycol methyl ether, and added
tetramethylrhodamine-5-(and -6-) C2 maleimide (TMRM) to react
with the remaining unreacted cysteine. This resulted in a homo-
genous dual-functionalisedDARPin (Fig. 2, ESI,† Fig. S61). Successful
dual modification was also demonstrated on HER2DARPin(N69C,
D72C) and mut4(N69C, D72C) (see ESI,† Fig. S62–S63).
Given the use of DARPins as binding proteins, it was
important to evaluate whether the structure and/or stability
had been aﬀected by introduction and modification of two
cysteine residues. Pleasingly, circular dichroism spectra (Fig. 3a) were
indistinguishable for wild-type HER2DARPin, HER2DARPin(N36C,
D105C) reacted with NMM, and dual-functionalised HER2DARPin-
(N36CTMRM, D105CAcEGMe). This implies that the structure is
unaﬀected by introduction and/or modification of the two cysteine
residues. Moreover, thermal unfolding data (Fig. 3b) showed an
unfolding transition at slightly higher temperatures for the dual
cysteine mutants, indicating that, if anything, the N36C, D105C
mutations may increase the stability of HER2DARPin.
Table 1 Reactivity of single-cysteine mutants with BrAcEGMe (5 eq.) in
PBS pH 7.4 for 1 h at 4 1C, and a single DARPin repeat highlighting the side-
chains of residues mutated
Mutation
Reaction with
BrAcEGMea (%)
D72C 100
G70C 18
N69C 0
K68C 16
V65C 5
E64C 17
E61C 57
L60C 4
H59C 29
a Determined by relative peak areas in mass spectrometry.
Fig. 1 Location of residues analogous to N69 and D72.
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In this communication, we have identified cysteine muta-
tions that can be sequentially modified to enable rapid and site-
selective dual modification of DARPins. We have shown that the
reactivity of the cysteine mutations is preserved when the muta-
tions are applied both to analogous positions within the same
protein, and to analogous positions on another DARPin. We
hence expect this strategy to be applicable across the class of
DARPins. To the best of our knowledge, no other strategy allows
site-selective, dual modification of DARPins in such a simple,
rapid and cost-eﬀective manner. Considering the academic,
diagnostic and therapeutic potential of DARPins, we anticipate
a number of applications to follow from our discovery.
We gratefully acknowledge the Wellcome Trust, MRC, RCUK,
EPSRC and UCLB for support of our programme, and Justin
Molloy for helpful discussions.
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Fig. 3 (a) Circular dichroism spectra of HER2DARPin variants, and (b) thermal
unfolding of HER2DARPin variants.
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